Federal Policy Shocks: CMS Postpones BALANCE Model, Extends Medicare GLP-1 Bridge Through 2027, and Faces Ethics Scrutiny

The regulatory and reimbursement landscape for GLP-1 therapeutics has experienced major shifts, marked by the indefinite postponement of a permanent Medicare coverage model, the extension of the transitional $50-per-month pilot program, and federal ethics disclosures revealing presidential stock trades in Eli Lilly during key policy decisions.

CMS Postpones Permanent BALANCE Model, Extends $50/Month Bridge Program

In late April 2026, the Centers for Medicare & Medicaid Services (CMS) announced an indefinite postponement of the Medicare Part D component of the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth). Originally scheduled to debut in January 2027 to allow Part D sponsors to permanently cover GLP-1s for weight loss, the program was tabled due to low commercial plan participation:

"But not every federal decision ran in Lilly’s favor. The FDA requested additional safety data on liver toxicity associated with Foundayo. And by late April, CMS announced that the BALANCE Model’s Medicare Part D component would not launch as scheduled in January 2027, citing insufficient plan participation — a setback that sent Lilly and Novo Nordisk shares lower."

To compensate for this setback, CMS officially extended the Medicare GLP-1 Bridge Program through December 31, 2027 (it was initially designed as a short-term pilot through the end of 2026).

Launching on July 1, 2026, the Bridge program will provide eligible Medicare Part D beneficiaries nationwide with access to anti-obesity medications (such as Lilly's newly approved oral pill Foundayo and injectable Zepbound, and Novo Nordisk's Wegovy) for a flat $50 monthly copay. However, there is a major financial catch for retirees:

"It's also worth noting that, as the GLP-1 Bridge program operates outside of Medicare Part D plans, any money spent on these medications for weight loss won't count toward your Medicare Part D deductible or out-of-pocket maximum."

Ethics Disclosures Reveal Presidential Stock Trades in Eli Lilly

Newly published federal ethics filings have sparked intense scrutiny regarding the timing of government policy decisions and private financial trades. Disclosures made public on May 14, 2026, show that President Donald Trump's accounts purchased Eli Lilly stock on at least seven occasions during the first quarter of 2026:

"Federal ethics disclosures published recently show President Donald Trump’s accounts purchased Eli Lilly stock on at least seven occasions in the first quarter of 2026 — a period in which his administration took a series of actions that directly benefited the drugmaker’s obesity drug business... The first Lilly purchase on record occurred Jan. 6. Two days later, the deadline closed for drug manufacturers to submit applications to participate in CMS’ newly announced BALANCE Model..."

During this exact first-quarter window and shortly thereafter, the federal government took several highly favorable actions for Eli Lilly:

1. Expedited Approval of Foundayo: In April 2026, the FDA approved Lilly's oral non-peptide GLP-1 weight loss drug, Foundayo (orforglipron), in just 50 days—the fastest approval for a novel drug since 2002—utilizing the Commissioner's National Priority Voucher program.
2. Compounding Crackdown: The FDA moved to shut down the lower-cost compounded GLP-1 market, which had served as cheap competition (pricing at $150 to $300 per month compared to Lilly's $1,000+ list price). In April 2026, the FDA proposed formally excluding all three major GLP-1 compounds from the 503B bulk substances list, closing the last legal pathway for large-scale compounding pharmacies.

Strategic Takeaways for Investors

• Near-Term Revenue Protection: The extension of the $50/month Bridge program through 2027 ensures that Eli Lilly and Novo Nordisk will continue to see massive patient volume from the Medicare demographic, despite the delay of the permanent BALANCE model.
• Compounding Defeated: The FDA's planned exclusion of GLP-1s from the 503B list is a massive win for branded manufacturers, as it will force millions of patients off compounded formulations and back onto branded drugs (Zepbound, Wegovy, and Foundayo).
• The Rise of Oral Pills: Lilly's Foundayo is immediately available via its LillyDirect telehealth service, creating a highly streamlined, vertically integrated pipeline from prescription to delivery, though the FDA has requested additional safety data regarding potential liver toxicity.